OVARIAN CLEAR CELL ADENOCARCINOFIBROMA
Clinical trials for OVARIAN CLEAR CELL ADENOCARCINOFIBROMA explained in plain language.
Never miss a new study
Get alerted when new OVARIAN CLEAR CELL ADENOCARCINOFIBROMA trials appear
Sign up with your email to follow new studies for OVARIAN CLEAR CELL ADENOCARCINOFIBROMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy aims to extend life in recurrent ovarian cancer
Disease control OngoingThis study looked at whether adding the drug bevacizumab to standard chemotherapy after surgery helps people with recurrent ovarian, peritoneal, or fallopian tube cancer live longer. Over 1,000 participants were randomly assigned to receive chemo alone or chemo plus bevacizumab, …
Matched conditions: OVARIAN CLEAR CELL ADENOCARCINOFIBROMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 08:58 UTC
-
Weekly chemo may improve outcomes for advanced ovarian cancer patients
Disease control OngoingThis study tested two different ways of giving the chemotherapy drug paclitaxel (either once every three weeks or once a week) along with carboplatin, with or without the targeted drug bevacizumab, in 692 people with advanced ovarian, peritoneal, or fallopian tube cancer. The goa…
Matched conditions: OVARIAN CLEAR CELL ADENOCARCINOFIBROMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:04 UTC